Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -209.73% is 68% below its 3-year average of -125.03%, around the middle of its 3-year range (-437.38%–-66.37%).
As of the fiscal period ended Tuesday, June 30, 2026. 13.31% below its 12-month average of -185.09%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -209.73%.
RETURN ON EQUITY (ROE)
-209.73%
RETURN ON EQUITY (ROE) AVG TTM
-185.09%
RETURN ON EQUITY (ROE) AVG 3Y
-136.83%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-13.31%
CURRENT VS 3Y AVG
-53.27%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.15%
median of 642 covered companies
CURRENT VS SECTOR MEDIAN
-422.42%
vs the sector median at left
Genelux Corporation
Market Cap
$115.69M
Return on Equity (ROE)
-209.73%
TTM Avg
-185.09%
3Y Avg
-136.83%
5Y Avg
N/A
Market Cap
$114.81M
Return on Equity (ROE)
-478.26%
TTM Avg
-687.50%
3Y Avg
165.05%
5Y Avg
111.70%
Market Cap
$116.82M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
Market Cap
$114.49M
Return on Equity (ROE)
N/A
TTM Avg
129.36%
3Y Avg
-24207.46%
5Y Avg
-16163.58%
Market Cap
$117.53M
Return on Equity (ROE)
-105.40%
TTM Avg
-90.09%
3Y Avg
-60.23%
5Y Avg
-18.64%
Market Cap
$112.48M
Return on Equity (ROE)
-22.45%
TTM Avg
-22.96%
3Y Avg
-17.88%
5Y Avg
-19.06%
Market Cap
$118.99M
Return on Equity (ROE)
-57.47%
TTM Avg
-26.63%
3Y Avg
16.73%
5Y Avg
210.40%
Market Cap
$116.34M
Return on Equity (ROE)
-5.10%
TTM Avg
-4.24%
3Y Avg
-6.16%
5Y Avg
0.09%
Market Cap
$111.02M
Return on Equity (ROE)
-60.82%
TTM Avg
-19.88%
3Y Avg
-19.08%
5Y Avg
-15.27%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $115.69M | -209.73% | -185.09% | -136.83% | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.81M | -478.26% | -687.50% | 165.05% | 111.70% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.82M | -0.05% | -43.47% | 9.13% | -18.50% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $114.49M | N/A | 129.36% | -24207.46% | -16163.58% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | -105.40% | -90.09% | -60.23% | -18.64% |
| MaxCyte, Inc. (MXCT)vs › | $112.48M | -22.45% | -22.96% | -17.88% | -19.06% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.99M | -57.47% | -26.63% | 16.73% | 210.40% |
| BGM Group Ltd. (BGM)vs › | $116.34M | -5.10% | -4.24% | -6.16% | 0.09% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $111.02M | -60.82% | -19.88% | -19.08% | -15.27% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.84M | -93.44% | -8.16% | 13.24% | 13.24% |
ROE
-209.7%
ROA
-129.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -209.73% |
| 2026-03-31 | -138.64% |
| 2025-12-31 | -278.46% |
| 2025-09-30 | -171.45% |
| 2025-06-30 | -127.17% |
| 2025-03-31 | -98.88% |
| 2024-12-31 | -113.68% |
| 2024-09-30 | -83.59% |
| 2024-06-30 | -70.45% |
| 2024-03-31 | -170.93% |
| 2023-12-31 | -145.31% |
| 2023-09-30 | -104.15% |
| 2023-06-30 | -66.37% |
| 2023-03-31 | -437.38% |
